Sumitomo Dainippon
Community score
moreSumitomo Dainippon Pharma Co., Ltd. is a pharmaceutical company formed in 2005 by the merger of Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceutical Co., Ltd. Headquartered in Chuo-ku, Osaka, Japan, the company specializes in multiple business segments, including prescription and over-the-counter medications, psychiatric and neurological pharmaceuticals, oncology, and regenerative medicine/cell therapy. Additionally, the company has a significant presence in the international pharmaceutical market, notably through its subsidiaries. Sunovion Pharmaceuticals Inc., a United States-based firm, is recognized for its work in psychiatric and neurological medications. Moreover, Boston Biomedical Inc. is a subsidiary that focuses on oncology. Sumitomo Dainippon Pharma and its associated brands have crucial markets in Japan, the United States, and other parts of the world, and maintain a global presence across North America, Europe, and Asia. (Powered by AI)
Low-quality healthcare causes 6 million (Mn) deaths in developing countries1. Infectious diseases such as non-communicable diseases (NCDs) constitute a critical part of health issues in the developing world as they cause high morbidity and mortali...
Around 2 billion (Bn) people worldwide lack access to essential medications1;p1. At least 10% of the household budget of over 800 million (Mn) people goes into healthcare expenditure, and 100 Mn people are pushed to extreme poverty due to unafford...
To ensure strong institutions and the well-being of society, governments spend a considerable amount of the state's budget on public goods and services, which are funded by taxes paid by individuals and corporations1. Corporate taxes accounted for...
Globally, around 80% of wastewater is discharged without proper treatment1. Water pollution results in algal blooms in aquatic environments, which quickly increase nutrient levels that support plant and algae growth while reducing water oxygen lev...